Back to top
more

Intercept Pharmaceuticals, Inc. (ICPT)

(Delayed Data from NSDQ)

$89.92 USD

89.92
705,568

+1.71 (1.94%)

Updated May 3, 2019 04:00 PM ET

After-Market: $89.98 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Will Ocaliva Sales Dampen Intercept's (ICPT) Q4 Earnings?

by Zacks Equity Research

The recent weakness in lead drug Ocaliva sales due to safety issues may mar Intercept's (ICPT) performance in the fourth quarter.

    Intercept (ICPT) Stock Loses Sheen in 2017: What Lies Ahead?

    by Zacks Equity Research

    Intercept (ICPT) had a tough time in 2017 after news of death were out related to lead drug's Ocaliva's dosing. We do not expect a phenomenal revival in 2018 either.

      Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat

      by Zacks Equity Research

      Intercept's (ICPT) third-quarter results were encouraging as loss was narrower than expected while Ocaliva registered a sequential increase.

        Ekta Bagri headshot

        Intercept (ICPT) Reports A Narrower Q3 Loss

        by Ekta Bagri

        Intercept (ICPT) reported a narrower-than-expect loss in the third quarter as revenues surpassed expectations.

          What's in the Offing for Intercept (ICPT) in Q3 Earnings?

          by Zacks Equity Research

          Intercept Pharmaceuticals, Inc. (ICPT) is likely to see a dip in Ocaliva sales when it reports third-quarter results on Nov 1.

            Bristol-Myers (BMY), TARGET Extend Partnership for NASH Study

            by Zacks Equity Research

            Bristol-Myers Squibb (BMY) extended its strategic partnership with TARGET PharmaSolutions, Inc. for NASH study.

              Here's Why Intercept (ICPT) Stock Lost 37% So Far in 2017

              by Zacks Equity Research

              Shares of Intercept Pharmaceuticals (ICPT) have plunged 37% in the year so far due to safety issues regarding approved drug Ocaliva.

                Will Conatus Liver Disease Candidate Drive Long-Term Growth?

                by Zacks Equity Research

                Conatus' (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in the company's portfolio are a positive step toward driving growth.

                  Intercept (ICPT) Provides Safety Guidelines For Ocaliva

                  by Zacks Equity Research

                  Intercept Pharmaceuticals, Inc. (ICPT) provided a statement on the recent safety and dosing issues for lead drug Ocaliva and reinforced that the recommended dosing is safe.

                    Implied Volatility Surging for Intercept Pharmaceuticals (ICPT) Stock Options

                    by Zacks Equity Research

                    Surging implied volatility for Intercept Pharmaceuticals (ICPT) Stock makes it lucrative to the option traders.

                      Company News For Sep 25, 2017

                      by Zacks Equity Research

                      Companies in the news are: VSAR,CAG, CMP,ICPT

                        Intercept Pharmaceuticals (ICPT) in Focus: Stock Moves 8.6% Higher

                        by Zacks Equity Research

                        Intercept Pharmaceuticals, Inc. (ICPT) was a big mover last session, as the company saw its shares rise nearly 9% on the day.

                          Why Is Intercept Pharmaceuticals (ICPT) Down 3.9% Since the Last Earnings Report?

                          by Zacks Equity Research

                          Intercept Pharmaceuticals (ICPT) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                            Will Conatus Key Candidate Emricasan Drive Long-Term Growth?

                            by Zacks Equity Research

                            Conatus's (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in its portfolio are a positive step by the company to propel growth.

                              Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2

                              by Zacks Equity Research

                              Intercept Pharmaceuticals (ICPT) reported a narrower-than-expected loss in Q2 on the back of higher Ocaliva sales.

                                Can Horizon Pharma (HZNP) Spring a Surprise in Q2 Earnings?

                                by Zacks Equity Research

                                Horizon Pharma (HZNP) is set to report second-quarter results next week and we expect investor focus on sales of key drugs.

                                  Ekta Bagri headshot

                                  Intercept (ICPT) Reports a Narrower Q2 Loss

                                  by Ekta Bagri

                                  Intercept Pharmaceuticals (ICPT) reported a narrower-than-expected loss in the second quarter while sales beat estimates.

                                    Can Prothena (PRTA) Deliver a Beat this Earnings Season?

                                    by Zacks Equity Research

                                    Prothena Corporation plc (PRTA) is expected to report second-quarter results next week and we expect investor focus on pipeline updates.

                                      What's in the Cards for Aerie (AERI) This Earnings Season?

                                      by Zacks Equity Research

                                      Aerie Pharmaceuticals (AERI) is expected to throw light on updates on Rhopressa during its second-quarter earnings call on Aug 1.

                                        Can BioMarin (BMRN) Keep the Earnings Streak Alive in Q2?

                                        by Zacks Equity Research

                                        BioMarin Pharmaceutical Inc. (BMRN) is likely to see continued momentum in Vimizim and Kuvan sales backed by robust patient growth in Q2.

                                          Can Regeneron Pharma (REGN) Pull a Surprise in Q2 Earnings?

                                          by Zacks Equity Research

                                          Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release second-quarter 2017 results on Aug 3 and we expect focus on Eylea's performance.

                                            What's in Store for Endocyte (ECYT) this Earnings Season?

                                            by Zacks Equity Research

                                            Endocyte (ECYT) looks forward to shift its focus on CAR T-cell small-molecule drug conjugates (SMDCs) adaptor platform, the dual-targeted DNA crosslinker drug EC2629 in Q2.

                                              Can Intercept (ICPT) Beat Estimates this Earnings Season?

                                              by Zacks Equity Research

                                              Intercept Pharmaceuticals, Inc.'s (ICPT) lead drug Ocaliva's uptake has been encouraging and we expect the company to throw light on its label expansion when it reports second-quarter results.

                                                Will Radius Health (RDUS) Disappoint this Earnings Season?

                                                by Zacks Equity Research

                                                Radius Health Inc. (RDUS) is expected to throw light on the launch and uptake of its newly approved drug Tymlos when it reports second-quarter results.

                                                  Is a Beat in Store for Agenus (AGEN) this Earnings Season?

                                                  by Zacks Equity Research

                                                  Agenus Inc. (AGEN) will focus on the development of all its pipeline drugs as currently there are no marketed drug in its portfolio.